OBJECTIVES: Rheumatoid Arthritis (RA) is a seriously debilitating disease affecting 37 in every 1000 adult populations in China. We assessed symptoms, functionality, and quality of life in RA patients who are treated with Infliximab in China. METHODS: A multi-center study was conducted from June 2009 to October 2011 in RA patients at 37 urban hospitals in 21 cities in China. Symptoms were measured by morning stiffness, and pain Visual Analogue Scale (VAS) scores defined from 0 (no pain) to 100 (severe pain). The Health Assessment Questionnaire (HAQ) was used to measure functional status (scores 0-3). Quality of life was measured by the mental (MCS) and physical component summary (PCS) scores of the Short Form-12 (SF-12). Comparisons were made between patients who were treated Infliximab at baseline and follow ups (experienced-Infliximab group, EIG) and those who were not treated with Infliximab at baseline but went on Infliximab treatment at the follow ups (new-Infliximab group, NIG). RESULTS: Of the 427 RA patients, 48 (11.2%) used Infliximab before, 83% were female, and the average age was 45 years old. The average duration of RA was 6 years, with almost 40% patients suffering RA more than 5 years. At baseline, the mean scores reported from the patients in EIG were: morning stiffness 31min, pain 45, HAQ 0.65, MCS 47 and PCS 38, which were all significantly better than patients in NIG. After 14 weeks Infliximab treatment, NIG patients improved significantly in morning stiffness (-55.6min), pain (-38.5), HAQ (-0.6), MCS (-16.2) and PCS (-15.6) than baseline (all P<0.0001). CONCLUSIONS: RA patients using Infliximab have better quality of life and daily function activities than those not using Infliximab before. Our findings also indicate that, it is essential to continue or initiate treatment with Infliximab to improve outcomes and quality of life in RA patients in China.